Home / Leaderboard / ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
Daniel Schneeberger · Hedge Fund · Long/Short Equity
ADAR1 Capital Management, LLC is an Austin-based investment management firm founded in 2018 by Dr. Daniel Schneeberger. The firm specializes in the life sciences and biotechnology sectors, managing a concentrated portfolio of both public and private equity investments. ADAR1 leverages its team's deep scientific and medical expertise to identify mispriced opportunities through a rigorous fundamental research process. The firm is known for its high-conviction approach and has recently gained prominence for its shareholder activism, engaging with portfolio companies to optimize capital stewardship and strategic direction to drive long-term value.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +95.0% |
| YTD return | +33.1% |
| Sharpe ratio | 4.69 |
| Win rate | 54% |
| AUM | $1.1B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.1B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.adar1.com |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| ABVX | Abivax SA American Depositary Shares | 14.8% | +32.9% |
| PTGX | Protagonist Therapeutics Inc | 13.5% | +104.9% |
| ROIV | Roivant Sciences Ltd | 10.6% | +92.0% |
| IMVT | Immunovant Inc | 9.8% | +130.4% |
| CRNX | Crinetics Pharmaceuticals Inc | 8.6% | +120.5% |
| SEPN | Septerna, Inc. Common Stock | 4.3% | +89.0% |
| CYTK | Cytokinetics Inc | 4.1% | +27.1% |
| DNLI | Denali Therapeutics Inc | 4.1% | +29.8% |
| BEAM | Beam Therapeutics Inc | 3.4% | -2.0% |
| ZLAB | Zai Lab Ltd | 3.3% | +16.7% |
| SYRE | Spyre Therapeutics Inc. | 3.1% | +42.8% |
| AVR | Anteris Technologies Global Corp. Common Stock | 3.0% | -3.1% |
| MNPR | Monopar Therapeutics Inc | 2.6% | +59.6% |
| RVMD | Revolution Medicines Inc | 2.4% | +64.8% |
| VIR | Vir Biotechnology Inc | 2.2% | +0.1% |
| RYTM | Rhythm Pharmaceuticals Inc | 2.2% | +20.7% |
| REPL | Replimune Group Inc | 2.1% | -6.7% |
| INSP | Inspire Medical Systems Inc | 2.1% | +27.0% |
| AMLX | Amylyx Pharmaceuticals Inc | 1.9% | +118.2% |
| SRRK | Scholar Rock Holding Corp | 1.9% | +13.8% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 17, 2026 | SELL | CYTK | 4.3% → 4.1% |
| Aug 17, 2026 | BUY | RYTM | 2.1% → 2.2% |
| Aug 17, 2026 | BUY | ZLAB | 3.0% → 3.3% |
| Aug 17, 2026 | BUY | INSP | 2.1% → 2.1% |
| Aug 17, 2026 | SELL | ELVN | 1.8% → 0.0% |
Investment Style Analysis
ADAR1 Capital Management, LLC is widely recognized for employing a Long/Short Equity strategy. As of Aug 20, 2026, the firm oversees approximately $1.1B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Medical Instruments & Supplies sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 17, ADAR1 Capital Management, LLC made a significant move by reducing the position in CYTK. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
ADAR1 Capital Management's philosophy is rooted in deep fundamental research and scientific rigor within the biopharmaceutical space. The firm seeks to capitalize on transformative medical therapies and technologies by taking strategic, often concentrated, stakes in innovative biotechnology companies. By combining scientific backgrounds with institutional investing experience, ADAR1 identifies significant discrepancies between a company's intrinsic value and its market price. The firm employs a long/short equity strategy and frequently engages in event-driven and activist situations where it can influence corporate governance or capital allocation to unlock shareholder value.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with ADAR1 Capital Management, LLC.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +24.1%
- Glenview Capital Management, LLC — Larry Robbins · 3M +14.0%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +3.7%
- Redmile Group, LLC — Jeremy Green · 3M +19.6%
Frequently asked questions
How is the simulated portfolio for ADAR1 Capital Management, LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is ADAR1 Capital Management, LLC's largest holding?
As of the latest filing, ADAR1 Capital Management, LLC's top position is Abivax SA American Depositary Shares (ABVX), representing 14.8% of the portfolio. This reflects a high-conviction bet by the institution.
What is ADAR1 Capital Management, LLC's historical performance and risk profile?
Our simulation indicates a total return of +95.0% with a win rate of 54%. Notably, the portfolio maintains a Sharpe Ratio of 4.69, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does ADAR1 Capital Management, LLC primarily invest in?
ADAR1 Capital Management, LLC has a strong preference for the Biotechnology sector, which makes up 94.9% of their disclosed assets. The portfolio also has exposure to Medical Instruments & Supplies, indicating a specific thematic focus.
Is ADAR1 Capital Management, LLC's portfolio concentrated or diversified?
ADAR1 Capital Management, LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 38.9% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has ADAR1 Capital Management, LLC performed in 2026?
Our AI-simulated model portfolio for ADAR1 Capital Management, LLC tracks a Year-to-Date (YTD) return of +33.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Daniel Schneeberger manage ADAR1 Capital Management, LLC directly?
Yes, Daniel Schneeberger serves as the key portfolio manager for ADAR1 Capital Management, LLC, overseeing the investment strategy and final capital allocation decisions.